Use of buprenorphine for those with employer-sponsored insurance during the initial phase of the COVID-19 pandemic

To quantify weekly rates of use of buprenorphine for those with employer-based insurance and whether the rate differs based on county-level measures of race, historical fatal drug overdose rate, and COVID-19 case rate.

Source: Journal of Substance Abuse Treatment - April 7, 2021 Category: Addiction Authors: Jonathan Cantor, Andrew W. Dick, Rebecca Haffajee, Megan F. Pera, Dena M. Bravata, Bradley D. Stein, Christopher Whaley Source Type: research